Conference call and webcast to be held
tomorrow, June 27, 2024 at
8:30 a.m. ET/ 5:30 a.m. PT
LA
JOLLA, Calif. , June 26,
2024 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica")
(Nasdaq: CALC), a clinical-stage biopharmaceutical company focused
on developing novel calcium release-activated calcium (CRAC)
channel inhibition therapies for acute and chronic inflammatory and
immunologic illnesses, today announced that it will host a
conference call on Thursday, June 27,
2024 at 8:30 a.m. ET/
5:30 a.m. PT to discuss topline data
from the Company's Phase 2b CARPO
trial of Auxora™ in acute pancreatitis (AP) with accompanying
systemic inflammatory response syndrome (SIRS).
Conference Call and Webcast Details
Stockholders and
other interested parties may participate in the call by following
the instructions below. A live webcast of the event can also be
accessed in the "Upcoming Events" section of CalciMedica's IR
website at https://ir.calcimedica.com/. A replay of the webcast
will be available following the completion of the event.
Participant Webcast Link:
https://app.webinar.net/jDbvg4E9yPn
- Click on the webcast link and complete the online registration
form.
- Upon registering, you will be connected to the online
webcast.
Participant Dial-in Numbers: 1-800-836-8184 (US) and
1-646-357-8785 (international)
- If prompted by the operator, ask to join the CalciMedica Phase
2b CARPO Topline Data Readout
call.
About CalciMedica
CalciMedica is a clinical-stage
biopharmaceutical company focused on developing novel CRAC channel
inhibition therapies for inflammatory and immunologic diseases.
CalciMedica's proprietary technology targets the inhibition of CRAC
channels to modulate the immune response and protect against tissue
cell injury, with the potential to provide therapeutic benefits in
life-threatening inflammatory and immunologic diseases for which
there are currently no approved therapies. CalciMedica's lead
product candidate Auxora™ has demonstrated positive and consistent
clinical results in multiple completed efficacy clinical trials.
CalciMedica has completed a Phase 2b
trial (called CARPO – NCT04681066) in AP with SIRS and a Phase
2b trial (called CARDEA –
NCT04345614) in COVID pneumonia patients, continues to support the
ongoing Phase 1/2 AIPT study (called CRSPA – NCT04195347), with
data expected in 2025, and has initiated its Phase 2 study
(called KOURAGE – NCT06374797) in AKI with associated AHRF with
data expected in 2025. CalciMedica was founded by scientists from
Torrey Pines Therapeutics and the Harvard CBR Institute for
Biomedical Research, and is headquartered in La Jolla, CA. For more information, please
visit www.calcimedica.com.
CalciMedica Contact:
Investors and Media
Argot Partners
Sarah Sutton/Kevin Murphy
calcimedica@argotpartners.com
(212) 600-1902
View original content to download
multimedia:https://www.prnewswire.com/news-releases/calcimedica-to-host-conference-call-to-review-topline-data-from-phase-2b-carpo-trial-of-auxora-in-acute-pancreatitis-ap-302183691.html
SOURCE CalciMedica, Inc.